Disability and quality of life in headache: where we are now and where we are heading

Abstract

Headache disorders determine relevant personal and societal burden, and thus the use of patient-reported outcome measures (PROMs) investigating the level of disability and health-related quality of life (HRQoL) have been increasingly used in headache research. The aim of this review was to address the status of research on disability and HRQoL, by addressing results from recently published clinical trials as well as in longitudinal observational studies on headache patients. PubMed has been searched for papers in which measures of HRQoL and/or disability were used as primary or secondary outcome on adult subjects with primary headache, and published in 2010-2012. Among the 70 records retrieved, 12 papers were selected for narrative synthesis. They included data on 2,621 patients with episodic migraine with and without aura, chronic daily headache, and/or chronic migraine with and without medication overuse. The selected trials investigated the efficacy of different pharmacological prophylaxis, of some surgical approaches, of education programmes and osteopathic manipulative treatment; two studies reported longitudinal observations of patients currently under treatment. Overall, the results of our review showed that headache frequency as well as HRQoL and disability were positively impacted by treatment interventions; positive outcomes were less evident in two studies, and similar results were found in the two observational studies. Our findings confirmed that the most commonly used PROMs, including disease-specific tools to assess disability and HRQoL and SF-36, are sensitive to the beneficial effects occurring over time in functioning and quality of life domains in headache patients. They also suggest that the personal and societal costs of headache disorders are likely to be reduced when headache patients receive appropriate treatments and when continuity of care is offered. In terms of future directions, we note that the systematic use of appropriate PROMs should be encouraged both in the clinical practice and in the research field, as they offer a valid option to assess the global effect of treatments on patient-perceived sense of well-being and quality of performance.

Effectiveness of Therapeutic Patient Education for Adults with Migraine. A Systematic Review and Meta-Analysis of Randomized Controlled Trials

“…Additionally, all articles that analyzed this variable were of high methodological quality. This concept reflecting concern with the modification and enhancement of life attributes, for example, physical, political, moral and social environment; the overall condition of a human life [57]. Similar to the conclusions that we reached, Nash et al.…”

Types of Nasal Delivery Drugs and Medications in Iranian Traditional Medicine to Treatment of Headache

“…According to the studies of scientists incidence, prevalence as well as the individual and social costs of headache are significantly high all over the world (1) especially in low and middle-income countries (2). While the prevalence of headache is more than 47% (3) utilization of proper and continuous management in the treatment of headache will reduce the personal and social expenditures of headache disorders (4). Because of the side effects resulting from the oral drugs, physicians tend to use other delivery mechanisms such as nasal delivery administration (5).…”

Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab

“…2 Less-thanoptimal treatment may result in significant functional (physical, mental, and social) disability for people with migraine and economic burden for society. 3 The pathophysiology of migraine is complex and incompletely understood; however, recent advances show promise for new pharmacologic and behavioral interventions. 4 Over the last decade, calcitonin gene-related peptide (CGRP) monoclonal antibodies have been investigated for the prevention of migraine, and blocking the CGRP receptor has shown clinical benefit for the acute treatment of migraine attack.…”